MA-IMABIOTECH
8.6.2021 09:02:13 CEST | Business Wire | Press release
ImaBiotech Group today announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc. Colorado Springs and Salt Lake City sites. The integration of the expertise, innovation and analytical platforms of the companies to form a leading global bioanalytical services provider will provide a unique offering to pharmaceutical and cosmetic companies.
Encompassing unique proprietary drug and biomarker imaging (Mass Spectrometry Imaging), multi-omics, spatialomics capabilities and well-established high performance bioanalytical GLP services, the combined platforms will offer access to a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV. These services reduce the rate of failure and accelerate the development of safer therapies. In conjunction to the operation, the company received a majority investment from ArchiMed SAS (“Archimed”), a leading private equity fund focused on the healthcare sector.
This deal enables a continuing commitment to further extend these specialized capabilities, creating a major player focused exclusively on bioanalytical excellence where the deep-science paradigm, a relentless focus on customer service, and innovative proprietary technology will enable and accelerate therapeutic innovation for our clients.
“I am very pleased to expand our activities in North America and Europe with Pyxant Labs and Archimed,” said former founder and CEO of ImaBiotech, Jonathan Stauber, PhD. “Archimed brings exceptional healthcare expertise with insight into advanced bioanalytical services, and the combination of Pyxant Labs’ established bioanalytical capabilities with ImaBiotech’s innovative imaging technologies will provide a unique service offering to our customers in the US, Europe and Asia, representing a tremendous opportunity to grow in the CRO market.”
“ImaBiotech’s deep-science paradigm and focus on customer service were two essential characteristics in common with our business paradigms, which motivated us toward this combination,” commented Maurice Gaubatz, CEO of Pyxant Labs. "Joining forces with Jonathan’s organization bridges ImaBiotech’s unique mass spectrometry imaging capabilities with Pyxant Labs’ regulatory development bioanalytical services and provides coverage from early research through Phase IV development. The combined enterprise creates an international footprint and leading standing among CROs exclusively focused on mass spectrometry bioanalytical excellence.”
The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2021.
About ImaBiotech www.imabiotech.com
ImaBiotech is a bioanalytical CRO with facilities in Boston (MA, USA) and Lille (Eurasante Park, France). ImaBiotech combines innovative mass spectrometry imaging and spatial biology (histology, multi-omics, spatialomics) techniques in order to decipher the complexity of drug activities. The combination of unique capabilities with advanced digital pathology tools makes possible the measurement of drug activity and drug response, simultaneously, at the single cell level. This performance enables comprehensive drug efficacy evaluation from preclinical to clinical stages.
About Pyxant Labs www.pyxant.com
Founded in 2000, Pyxant Labs provides innovative bioanalytical solutions for advancing leading-edge and challenging drug development programs from translation through NDA approval. Utilizing high resolution mass spectrometry and traditional LC-MS/MS platforms, the Colorado Springs site is recognized for its fast-turnaround drug discovery services, unique expertise quantitating delivery mechanisms for RNA therapeutics, anticipatory customer service, and superior regulatory compliance.
About ArchiMed www.archimed-group.eu
ArchiMed is a leading private equity firm focused exclusively on the healthcare industry. ArchiMed’s strategy is based upon healthcare specialization, integrated private equity, medical and operating expertise, and its unique trans-Atlantic platform that supports growth through internationalization. Over the last 20 years, ArchiMed’s leadership team has directly managed and invested in over 40 small to large-size healthcare companies globally, representing over €5 billion of invested capital. ArchiMed currently manages nearly €2 billion in assets across four funds, small-cap focused MED I and MED II, gene & cell therapy focused PolyMED and mid-cap-focused MED Platform I. The latter is Europe’s largest healthcare fund at €1 billion. ArchiMed is an impact investor and a signatory of the Principles for Responsible Investment , pledged to uphold the United Nations’ Sustainable Development Goals .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005490/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service18.3.2026 16:30:00 CET | Press release
Boomi™, the data activation company, today announced it has been recognized as a Leader and positioned highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS). This marks the 12th consecutive time Boomi has been named a Leader– the longest recognized vendor in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318987091/en/ Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service Boomi attributes its continued industry recognition to its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in integration and automation, APIM, agent management, and data management to help enterprises transform fragmented systems and data into orchestrated processes and governed agentic workflows. Recent i
Laserfiche Announces 2026 Run Smarter® Award Winners18.3.2026 15:17:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the winners of the 2026 Laserfiche Run Smarter® Awards. These awards celebrate the visionaries and trailblazers who are redefining the possible, using Laserfiche to break down operational silos and catalyze a new era of enterprise-wide productivity. From a large city reimagining criminal justice to a financial services firm’s innovative use of AI for smarter service delivery: The winners enhance productivity, reimagine processes and improve lives with Laserfiche technology. “The true power of Laserfiche has always been in how it unlocks value — whether that is through delivering actionable intelligence, cost savings, or reclaimed time to put toward innovation,” said Karl Chan, CEO of Laserfiche. “This year’s honorees are at the forefront of information management, with many of them leveraging cloud and AI technology to modernize processes and achieve business transformation.” Congratulations to t
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 14:30:00 CET | Press release
I-Pulse Acquires California Capacitor Specialist CSI Technologies to Advance Disruptive Pulsed Power ApplicationsCSI Acquisition Secures Strategic Technologies Central to I-Pulse’s Pulsed Power Roadmap Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse str
Elliptic Integrates With Tempo, the Payments-First Blockchain18.3.2026 14:15:00 CET | Press release
Elliptic, the leader in digital asset decisioning, today announced full blockchain coverage for Tempo, the payments-first Layer-1 blockchain incubated by Stripe and Paradigm. With this integration, compliance and investigation teams gain full visibility into one of the most significant expansions of real-world financial activity onto blockchain infrastructure. "We're excited to have Elliptic providing compliance infrastructure on Tempo from day one. As payments move onchain at scale, builders and their customers need real-time tools to meet regulatory requirements without slowing down." – Nischay Upadhyayula, GTM, Tempo Tempo is a Layer-1 blockchain designed for real-world payments at scale, with sub-second finality and high throughput. Incubated by Stripe and Paradigm, Tempo is built for the transaction volumes that global commerce demands. Elliptic’s blockchain analytics platform is purpose-built to analyse on-chain data at this scale. “Tempo’s payment-specific blockchain infrastruct
RecVue Completes Acquisition of AiVidens18.3.2026 14:04:00 CET | Press release
Transaction advances RecVue RevOS into a unified revenue-to-cash Revenue Operating System RecVue, the leader in AI-powered billing and revenue management platforms for complex enterprise monetization, today announced it has completed the acquisition of AiVidens. By acquiring the cash management and collections platform, RecVue will enable enterprises to move beyond simple revenue automation to unify contract governance, billing, collections, revenue compliance, revenue sharing, and liquidity management all within a single revenue operating system. “This acquisition furthers our strategy to close the structural gap between revenue and cash,” said Nishant Nair, Founder and CEO of RecVue. “CFOs today are accountable not only for revenue accuracy, but for liquidity performance and working capital efficiency. With AiVidens, we are extending RevOS to connect commercial activity directly to cash realization.” While tasked with these widening responsibilities, enterprise CFOs struggle with dis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom